These clinical studies are extremely beneficial because if successful, they could provide us with insight as to how well modified immune cells can attack different kinds of cancers, while using a gene-editing technique that is more simple and efficient than others. This article states that the first clinical trial in China could initiate a sort of "biomedical duel" between China and the United States, as they often compete with each other in the advancement of all types of technology. The prospect of this "biomedical duel" is exciting because this type of competition may facilitate quicker progress in cancer treatment research. In the United States the first CRISPR clinical trial is expected to start in the beginning of 2017, as well as more clinical trials in China. I think that this type of progression gives hope to many cancer patients and other people suffering from diseases that could benefit from gene modification treatments.